VR Logo

AlloVir Inc. (ALVR) download report


Healthcare | Biotechnology & Pharma Research

AlloVir Inc. (ALVR) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.

IPO Date: 30-Jul-2020

Exec. Chairman: Mr. David L. Hallal

CEO & Director: Dr. Diana M. Brainard M.D.

Listing: NASDAQ: ALVR

Country: United States

Headquarters: Waltham, MA

Website: https://www.allovir.com

Key Facts

Market cap: $270.17 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-184.90 Mln

Cash: $201.38 Mln

Total Debt: $23.13 Mln

Insider's Holding: 49.12%

Liquidity: Low

52 Week range: $3.17 - 26.41

Shares outstanding: 65,417,500

Stock Performance

Time Period AlloVir (ALVR) S&P BSE Sensex S&P Small-Cap 600
YTD-65.92-8.79-19.61
1 month19.19-4.72-9.38
3 months-37.54-12.34-15.04
1 Year-77.781.24-17.73
3 Years--10.015.82
5 Years--11.235.47
10 Years--11.779.50
As on 05-Jul-2022
Year AlloVir (ALVR) S&P Small-Cap 600 S&P BSE Sensex
2021-66.3425.2721.99